The term higher-risk is used arbitrarily in clinical practice to indicate more advanced stages of myelodysplastic syndromes (MDS). The intermediate-1 and high risk groups under the International Prognostic Scoring System (IPSS) are typically considered as higher-risk disease; while with the revised IPSS (IPSS-R), the high and very high risk groups would be under the category of higher-risk disease. Treatments considered for this group of patients are usually different to, and more aggressive than those offered for the lower-risk disease. In addition, sometimes under specific circumstances, patients with lower-risk disease are treated with such aggressive therapies. This chapter will provide a comprehensive review of management strategies for higher-risk MDS. A discussion regarding logical consideration of more aggressive therapies in lower-risk disease as well as choice of therapy in higher-risk patients will be offered. The chapter will also review clinically relevant details of agents and regimens used in the treatment of higher-risk MDS. Moreover, extensive description of clinical trials and available data on specific agents used in this setting will be provided.
|Original language||English (US)|
|Title of host publication||Myelodysplastic Syndromes|
|Subtitle of host publication||From Pathogenesis to Diagnosis and Therapy|
|Publisher||Nova Science Publishers, Inc.|
|Number of pages||28|
|State||Published - Jan 1 2013|
ASJC Scopus subject areas